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Abstract
Vitamin D insufﬁciency and deﬁciency have been associated with an increased risk of adverse pregnancy outcomes. Controversy remains as
ﬁndings have been inconsistent between disparate populations. The aim of this study was to investigate the relationship between vitamin D
status and pregnancy outcomes in a large, prospective pregnancy cohort. 25-Hydroxyvitamin D concentration was analysed in serum samples
collected at 15 weeks of gestation from 1710 New Zealand women participating in a large, observational study. Associations between
vitamin D status and pre-eclampsia, preterm birth, small for gestational age (SGA) and gestational diabetes were investigated. The mean
25-hydroxyvitamin D concentration was 72·9 nmol/l. In all, 23% had 25-hydroxyvitamin D concentrations <50 nmol/l, and 5% of participants
had concentrations <25 nmol/l. Women with 25-hydroxyvitamin D concentrations <75 nmol/l at 15 weeks of gestation were more likely to
develop gestational diabetes mellitus than those with concentrations >75 nmol/l (OR 2·3; 95% CI 1·1, 5·1). However, this effect was not
signiﬁcant when adjustments were made for BMI and ethnicity (OR 1·8; 95% CI 0·8, 4·2). 25-Hydroxyvitamin D concentration at 15 weeks was
not associated with development of pre-eclampsia, spontaneous preterm birth or SGA infants. Pregnancy complications were low in this
largely vitamin D-replete population.
Key words: Vitamin D: Gestational diabetes mellitus: Pre-eclampsia
Much progress has been made in the screening, diagnosis and
management of important pregnancy disorders, but little pro-
gress has been made in the prevention of such disorders. Pre-
eclampsia remains the second most common cause of maternal
death worldwide(1). Prematurity, mostly due to spontaneous
preterm birth, is the leading cause of death among infants
worldwide(2). This is followed by growth restriction in term
infants(3). Furthermore, infants born preterm or with low birth
weight have an increased risk of CVD and metabolic diseases
later in life, the leading cause of death in adulthood(4). The
incidence of gestational diabetes mellitus (GDM) is increasing
rapidly worldwide(5) and is associated with lifelong risks of
metabolic disease in both mother and baby(6,7).
An association between low vitamin D and adverse
pregnancy outcomes was ﬁrst identiﬁed in the early 2000s(8);
consequently, vitamin D has been postulated as a possible
intervention strategy to reduce pregnancy complications.
A recent meta-analysis found that low vitamin D, deﬁned
variably by the authors of included studies, was associated with
an increased likelihood of pre-eclampsia (OR 1·79; 95% CI 1·25,
2·58), small-for-gestational age (SGA) babies (OR 1·85; 95% CI
1·52, 2·26) and GDM (OR 1·49; 95% CI 1·18, 1·89)(9). Preterm birth
was not included as an outcome. However, most included studies
did not correct for important confounders, and those that did
were small. In addition, vitamin D deﬁciency was variably deﬁned
between 35 and 80nmol/l or analysed in late pregnancy(9).
Late pregnancy may not be the optimum time to measure
vitamin D, as it is believed that the origins of most late pregnancy
disorders are in early pregnancy. Moreover, the expressions of
both CYP25B1 (the vitamin D activating enzyme) and vitamin D
Abbreviations: GDM, gestational diabetes mellitus; NZ, New Zealand; SCOPE, Screening for Pregnancy Endpoints study; SGA, small for gestational age.
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nuclear receptor(10) are highest during the ﬁrst trimester. In the
current study, factors that may alter the development of
pregnancy conditions were investigated at the beginning of
the second trimester – a time when critical vascular develop-
ment of the placenta occurs(11).
The aim of this study was to investigate the relationship between
early pregnancy 25-hydroxyvitamin D concentration and sub-
sequent development of pre-eclampsia, spontaneous preterm birth,
SGA and GDM in a large, well-phenotyped, prospective cohort.
Methods
Participants
Samples were collected from Auckland participants recruited to
the Screening for Pregnancy Endpoints study (SCOPE) between
2005 and 2008. SCOPE is an international, prospective, pregnancy
study of nulliparous women, which aims to identify early preg-
nancy predictors of late pregnancy complications(12). The study
was approved by the Auckland University Ethics Committee
(AKX/02/00/364). The trial was registered with the Australia New
Zealand clinical trial registry (ACTRN 12607000551493).
Non-fasting serum samples were collected at 15 weeks of
gestation and stored at −80°C. At the time of sample collection,
participants were asked whether they took multivitamins, and the
brand used was recorded. Data on socio-economic status(13) were
recorded, and participants were asked whether they smoked.
Participants were also asked to rate their physical activity (over
the previous 3 months) as vigorous, moderate, recreational
walking or no physical activity, and the frequency at which they
engaged in physical activity was recorded. Data were entered into
an Internet-accessed, password-protected, centralised database
with complete audit train (MedSciNetAB).
Pre-eclampsia was diagnosed according to the International
Society for the Study of Hypertension in Pregnancy criteria(14)
as gestational hypertension (systolic blood pressure of
≥140mmHg and/or diastolic blood pressure of ≥90mmHg on
at least two occasions) with proteinuria or any multisystem
complication of pre-eclampsia(15). SGA was deﬁned as weight
below the 10th customised birth weight centile(16), and spon-
taneous preterm birth was deﬁned as delivery before 37 weeks
of gestation. Women were screened for GDM between 24 and
28 weeks of gestation with a non-fasting 50-g polycose chal-
lenge in community laboratories, according to the Auckland
District Health Board Guidelines. Those with a positive poly-
cose test (deﬁned as 1 h post-challenge glucose of ≥7·8mmol/l)
were further tested with a fasting 75-g oral glucose tolerance
test (OGTT). A total of forty-four women considered to be at
high risk of GDM underwent an OGTT without a polycose test.
GDM was diagnosed if fasting glucose was ≥5·5 nmol/l or if the
2-h post-glucose challenge showed values ≥9·0mmol/l.
Sample analysis
Serum samples were prepared using PhreeTM phospholipid
removal cartridges (Phenomenex) after addition of the internal
standard deuterated 25-hydroxyvitamin D3 (Isosciences). Separa-
tion of 25-hydroxyvitamin D3 and 3-epi-25-hydroxyvitamin D3 was
achieved with a KinetexTM pentaﬂurophenyl 100× 3-mm 2·6-
μm HPLC column (Phenomenex). 25-Hydroxyvitamin D3, c3-
epi 25-hydroxyvitamin D3 and 25-hydroxvitamin D2 were ana-
lysed by liquid chromatography tandem MS (Finnigan TSQ
Quantum Ultra™ triple quadrupole mass spectrometer; Thermo
Electron Corporation). Total 25-hydroxyvitamin D was calcu-
lated by the sum of these three compounds. The intra- and
inter-assay CV were 7·3 and 4·9% for 25-hydroxyvitamin D3 and
8·2 and 5·8% for 25-hydroxyvitamin D2, respectively. Quality
control was ensured through participation in the Vitamin D
External Quality Assessment Scheme DEQAS programme
operating out of Charing Cross Hospital, London(17), and the
use of commercially available control materials of known vita-
min D concentration. Vitamin D binding protein (VDBP) was
analysed using an ELISA from R&D systems.
Statistical analysis
All statistical analyses were performed in SPSS (IBM) version 21.
Normality was tested by assessing the histogram and tests for
skewness and kyphosis. Continuous variables are reported as
mean values and standard deviations. χ2 Tests were performed for
categorical variables and the t test for continuous variables.
Fisher’s exact test was performed when χ2 was not appropriate.
The dates of sample collection were categorised into seasons as
follows: summer, December to February; autumn, March to May;
winter, June to August; and spring, September to November.
Logistic regression analyses were performed to determine whe-
ther 25-hydroxyvitamin D concentration was associated with the
development of GDM, pre-eclampsia, SGA and spontaneous
preterm birth. Only participants screened for GDM were included
in the analysis for GDM. Multiple logistic regression with back-
wards selection using the likelihood ratio criteria was used to
incorporate known risk factors for adverse pregnancy outcomes,
including age, BMI, ethnicity, smoking status and socio-economic
status. The analysis was performed with 25-hydroxyvitamin D as
a continuous variable and vitamin D level as a categorical vari-
able. Vitamin D categorical variables were created with cut-offs at
25, 50 and 75nmol/l. These cut-offs were based on the Institute of
Medicine deﬁnition of deﬁciency (<50nmol/l)(18) and the Endo-
crine Society clinical practice guidelines deﬁnition of insufﬁciency
(<75nmol/l) and severe deﬁciency (<25nmol/l)(19). Hosmer–
Lemeshow goodness of ﬁt was performed to test the adequacy of
the model (a value of 1 indicates perfect correspondence
between the model-predicted and observed risks).
Results
A total of 2065 women were recruited to the SCOPE study in
Auckland. Of those women, 355 did not have 15-week serum or
plasma samples for analysis. In total, 1710 women were included
in the ﬁnal analysis. Of those, 166 participants were not screened
for GDM, and 1544 women were included in the ﬁnal analysis for
that outcome. Among them, thirty-two (2·1%) women were
diagnosed with GDM, seventy-three (4·2%) women were diag-
nosed with pre-eclampsia, seventy (4·1%) women spontaneously
delivered preterm infants and 170 (9·9%) women delivered SGA
infants (Fig. 1). The majority of women were of New Zealand
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(NZ) European ethnicity (83·8%). The remaining ethnic groups
were Asian (n 91, 5·3%), Maori (n 57, 3·3%), Indian (n 65, 3·8%),
Paciﬁc Islanders (n 34, 2·0%) and African (n 30, 1·8%) (combined
as ‘other ethnicities’ in Table 1).
Overall, 55% of women took multivitamin supplements
containing vitamin D; one brand contained vitamin D2 and was
taken by twenty women. The dose of vitamin D supplement
ranged from 5 to 20 μg/d. Women who took multivitamin
supplements containing vitamin D had signiﬁcantly higher
25-hydroxyvitamin D concentrations than those who did not
(93·6 (SD 29·6) v. 75·8 (SD 32·6) nmol/l; P< 0·001). The propor-
tion of women who took multivitamin supplements containing
vitamin D was lower among those who developed GDM,
although this was not statistically signiﬁcant (38 v. 55%; P= 0·4).
Concentrations of 25-hydroxyvitamin D were approximately
normally distributed (skewness −0·03, SE 0·05; kurtosis
−0·3, SE 0·1). Just over half of the sample (53%) had
25-hydroxyvitmamin D concentrations <75 nmol/l, 22·7% had
concentrations <50 nmol/l and 4·4% had concentrations
<25 nmol/l. There was a signiﬁcant difference in the mean BMI
between women who developed GDM and pre-eclampsia and
women who did not (P= 0·001) (Table 1). The prevalence of
GDM and pre-eclampsia varied signiﬁcantly depending on
ethnicity (P= 0·02 and 0·05, respectively), with Indian women
having the highest prevalence of GDM and NZ European women
the lowest. Paciﬁc Island women had the highest prevalence of
pre-eclampsia. The mean total serum 25-hydroxyvitamin D
concentration was lower in those who developed GDM than in
those who did not (61·6 (SD 23·9) nmol/l as compared with
72·9 (SD 27·0) nmol/l; P= 0·03) but not lower in women
who developed pre-eclampsia (68·1 (SD 27·8) nmol/l) or
delivered preterm (73·7 (SD 27·5) nmol/l) or SGA infants (70·6
(SD 29·0) nmol/l) (Table 1). Of women who developed GDM,
72% had a concentration <75nmol/l and 22% had a concentra-
tion <50nmol/l. Women of European decent were the largest
ethnic group; there was no signiﬁcant difference in mean total
25-hydroxyvitamin D in those who developed GDM and in those
who did not (70·6 v. 75·9nmol/l; P= 0·35).
There was an increased likelihood of developing GDM if total
25-hydroxyvitamin D was <75 nmol/l (OR 2·3; 95% CI 1·1, 5·1).
However, after adjustment for BMI and ethnicity, this difference
was not signiﬁcant (adjusted OR 1·8; 95% CI 0·8, 4·2). There
was no increased likelihood of developing any of the adverse
pregnancy outcomes at concentrations <50 and <25 nmol/l
(Table 2).
On logistic regression, 25-hydroxyvitamin D concentration as
a continuous variable was associated with an increased like-
lihood of developing GDM with a 1% increase in risk for every
1 nmol/l reduction in 25-hydroxyvitamin D (OR 1·01; 95% CI
1·01, 1·03; P= 0·03) (Table 2). Following inclusion of BMI and
ethnicity in the model, the relationship between
25-hydroxyvitamin D concentration and GDM was no longer
signiﬁcant. Using the International Association of Diabetes in
Pregnancy criteria for the diagnosis of GDM increased the
number of GDM cases (n 48) but did not increase the
signiﬁcance of the relationship with 25-hydroxyvitamin D.
In a logistic regression model including vitamin D and
season, vitamin D was not a signiﬁcant contributor. After
adjustment for BMI and ethnicity, season remained a signiﬁcant
risk factor for GDM (adjusted OR 4·2; 95% CI 1·3, 13·0;
P= 0·04). Season was also a signiﬁcant predictor of developing
pre-eclampsia (adjusted OR 2·2; 95% CI 1·0, 4·5; P= 0·04) and
delivering SGA infants (adjusted OR 2·1; 95% CI 1·3, 3·5;
P= 0·003). After adjustment for BMI and ethnicity, exercise
(P= 0·1), age (P= 0·7), socio-economic status (P= 0·8) and
smoking status (P= 0·2) were not statistically associated with
GDM and are not included in the model shown in Table 2.
VDBP was analysed, and free 25-hydroxyvitamin D was
calculated for a subgroup of participants (32 GDM with
4 BMI- and ethnicity-matched controls). VDBP concentration
was signiﬁcantly correlated with 25-hydroxyvitamin D
concentration (P= 0·03). No correlation between calculated free
25-hydroxyvitamin D and GDM was found.
Discussion
In this large, well-phenotyped cohort, we found that
25-hydroxyvitmain D concentration was not lower at 15 weeks
of gestation in women who later developed pre-eclampsia,
spontaneous preterm birth or who had SGA infants.
Concentrations were lower in women who developed
GDM but did not predict GDM when adjusted for BMI and
ethnicity.
This cohort differs from most other pregnancy cohorts in that
it is relatively vitamin D replete. Although 23% of Auckland
SCOPE participants were vitamin D deﬁcient (25-hydro-
xyvitamin D<50 nmol/l), half to more than 90% of pregnant
women have been found to be deﬁcient in previous
studies(20–22). The SCOPE Auckland cohort may be more
vitamin D replete in comparison with the obstetric Auckland
population and the wider New Zealand population. Auckland is
in the northern region of New Zealand where it is estimated
that 24min of hand and face exposure to the sun daily is
adequate. This is not the case for much of New Zealand’s
geographical distribution(23). NZ European women had the
highest 25-hydroxyvitamin D concentrations by ethnicity, and
although they represented 83·8% of Auckland Scope, at the
time of sample collection, they represented 49·0% of women
delivering at Auckland City Hospital(24), and according to the
most recent National Women’s report they represented 44% of
women delivering at Auckland city hospital(25).
32 GDM
1544 screened 
for GDM
73 spontaneous
preterm birth
170 small for
gestational age
73 pre-eclampsia
1715 25-hydroxyvitamin D 
analysed
2065 women
Fig. 1. Cohort flow diagram of Auckland SCOPE participants from recruitment
at 15 weeks’ gestation.
Maternal vitamin D and pregnancy outcomes 1411
http://dx.doi.org/10.1017/S0007114516003202
Downloaded from http:/www.cambridge.org/core. University College Cork, on 09 Nov 2016 at 09:40:11, subject to the Cambridge Core terms of use, available at http:/www.cambridge.org/core/terms.
Table 1. Maternal characteristics, 25-hydroxyvitamin D concentration at 15 weeks of gestation and pregnancy outcomes
(Numbers and percentages; mean values and standard deviations)
All n 1710 Pre-eclampsia n 72 sPTB n 73 SGA n 170 GDM n 32
n % n % n % n % n %
Age (years)
Mean 30·3 30·0 30·8 31·1 30·8
SD 4·7 5·0 4·8 4·8 5·1
BMI (kg/m2)
Mean 24·8 26·9 24·9 25·4 27·4
SD 4·2 4·8 4·5 5·1 5·2
Ethnicity P=0·05 P= 0·15 P=0·18 P=0·02
NZ European 1433 83·8 54 3·8 67 4·7 137 9·6 21 1·6
Other ethnicities 277 16·2 18 6·5 6 2·1 33 11·9 11 4·0
Season at sample collection P=0·01 P=0·9 P=0·02 P=0·03
Summer 452 26·4 12 2·7 22 4·9 28 6·2 7 2·0
Autumn 397 23·2 21 5·3 16 4·0 46 11·6 4 0·8
Winter 510 29·8 19 3·7 20 3·9 53 10·4 6 1·2
Spring 351 20·5 20 5·7 15 4·3 43 12·3 15 3·6
Total 25-hydroxyvitamin D at 15 weeks of gestation (nmol/l) P= 0·1 P=0·7 P= 0·2 P=0·03
Mean 72·9 68·1 73·7 70·6 61·6
SD 27·0 27·8 27·5 29·0 23·9
Total 25-hydroxyvitamin D level at 15 weeks of gestation
<25nmol/l 76 <5 <5 12 15·8 <5
25–49·9nmol/l 292 17·1 15 5·1 14 4·8 35 12·0 8 2·7
50–74·9nmol/l 508 29·7 24 4·7 16 3·1 43 8·5 14 2·8
>75nmol/l 834 48·8 29 3·4 39 4·7 80 9·6 9 1·1
sPTB, spontaneous preterm birth; SGA, small for gestational age; GDM, gestational diabetes mellitus.
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In the SCOPE cohort, there are limited proportions of women
with vitamin D concentrations <25 nmol/l (4·4%). We believe
that this has not signiﬁcantly altered the association of other
outcomes, given that previous studies investigating the rela-
tionship between 25-hydroxyvitmain D concentration and
pregnancy outcomes have reported both positive and negative
associations in populations with high and low prevalence of
vitamin D deﬁciency (summarised in Table 3).
In some vitamin D-replete populations of pregnant women,
signiﬁcant associations with GDM(26) and SGA(27) have been
found. In a similarly replete population, investigators found no
association between vitamin D status and pregnancy outcomes
including pre-eclampsia, SGA, preterm birth and GDM(20).
However, in vitamin D-deﬁcient populations, no association
between 25-hydroxyvitamin D concentration and SGA(30) and
GDM(22) was found (Table 3).
The main limitation to our study was the comparatively low
prevalence of late pregnancy disorders, particularly GDM; this
was due to the purpose for which SCOPE was established – that
is, to investigate predictors of late pregnancy disorders in early
pregnancy in low-risk, nulliparous women(12). We did not have
data on sunlight exposure – a factor that contributes most to
25-hydroxyvitamin D concentration. Given the lack of an
association between vitamin D and pregnancy outcomes in this
study, we do not believe these data would have altered the
outcome.
Our ﬁndings are supported by a recent meta-analysis on trials
of vitamin D supplementation in pregnancy and pregnancy
outcomes(31). There was no difference in the incidence of
pre-eclampsia, preterm birth, low birth weight and GDM with
vitamin D supplementation in pregnancy. However, a recently
updated Cochrane systematic review on vitamin D supple-
mentation in pregnancy found a reduced incidence of pre-
eclampsia, preterm birth and low birth weight (<2500 g)(32).
These results were sensitive to the inclusion, or not, of trials
using low-dose vitamin D supplementation. This highlights the
need for pregnancy outcomes to be evaluated in ongoing,
randomised trials of vitamin D supplementation in pregnancy.
There may be a number of reasons for the inconsistency in
the literature. The aetiology of pre-eclampsia, preterm birth,
SGA and GDM are not fully understood and is likely to be multi-
factorial. Vitamin D deﬁciency maybe an important predictor in
some populations and not in others. For example, because
vitamin D increases intestinal absorption of Ca, in a population
where dietary calcium is particularly low, vitamin D status
maybe an important predictor for developing pre-eclampsia but
not when dietary Ca is adequate(30). Genetic polymorphisms of
the vitamin D nuclear receptor and vitamin D binding protein
have been associated with a wide variety of conditions(33,34),
and may explain why a study in the USA found that vitamin D
deﬁciency (<37·5 nmol/l) was a risk factor for SGA in white
women (adjusted OR 7·5; 95% CI 1·8, 31·9) but not in black
women (adjusted OR 1·5; 95% CI 0·6, 3·5)(28). This study found
a non-linear association between 25-hydroxyvitamin D con-
centration and SGA, with an increased risk of SGA with con-
centrations >75 nmol/l (OR 2·2; 95% CI 1·2, 3·8).
Vitamin D may be a surrogate marker for other causative
factors that vary between populations, particularly those withTa
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seasonal variation. We found a signiﬁcant variation in GDM,
pre-eclampsia and SGA with season that was not explained by
25-hydroxyvitamin D concentration. Factors that vary with
season may be population speciﬁc, especially dietary patterns.
A study on pregnant women in New Zealand found signiﬁcant
variations in macronutrient and micronutrient intakes according
to season, including lower dietary Ca consumption in winter
and summer(35). A recent study has demonstrated seasonal
variation in gene expression in human lymphocytes and adi-
pocytes(36). These cell types play important roles in insulin
sensitivity and inﬂammation. Although it is not yet known how
cell function is affected, these variations in gene expression may
be relevant to GDM and pre-eclampsia risk. Others have found
a signiﬁcant variation in the prevalence of pre-eclampsia with
season(37). In our data, the association of season and GDM
remains signiﬁcant after adjustment for BMI and ethnicity,
consistent with greatest risk if early pregnancy occurs during
the winter and early spring, when 25-hydroxyvitamin D con-
centrations are lowest.
In this vitamin D-replete pregnancy cohort, 25-hydroxyvitamin D
concentration did not predict pregnancy outcomes including
pre-eclampsia, SGA, spontaneous preterm birth and GDM
when adjustments were made for confounders. Season was
identiﬁed as a signiﬁcant predictor for GDM. This does not
exclude a potential contribution of vitamin D to GDM risk, but
also raises the possibility of other pertinent seasonal factors.
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